The ERCUSYN (European Register on Cushing’s Syndrome) project, is aimed at registering clinical data on patients with Cushing’s syndrome throughout Europe, with the following objectives:
1) to set up a European Register on the diagnosis, management, quality of life and outcomes of patients affected by Cushing’s syndrome across European countries;
2) to define relevant health indicators and information to develop epidemiological data at EU level;
3) to collect data on the impact of Cushing’s syndrome on Health-related Quality of Life;
4) to define the optimal diagnosis strategy and the short and long term therapeutic goals;
5) to increase awareness about the disease by disseminating what has been learnt from the project;
6) to evaluate the persistent consequences of having suffered Cushing’s syndrome.

ERCUSYN DATA

-New article: An article on mortality in Cushing’s syndrome has recently been published in the European Journal of Endocrinology.

High mortality within 90 days of diagnosis in patients with Cushing’s syndrome: results from the ERCUSYN registry

Authors: Elisa Valassii, Antoine Tabarin, Thierry Baulieu, Richard A Feelders, Martin Bertinieri, Romana Hurria-Jan, Makis Tobi, Sabia Zacharewska, Susan M Poult, Stéphanie Tropea, Philippe Chanson, Mario Chambon, Ezio Ghigo, and the ERCUSYN Study Group.

By December 2019, 1882 patients have been included, with partners from 53 centers in 26 countries (database developed by Lohmann & Birkner Health Care Consulting GmbH –L&B).

See link to map with details of all centers: https://www.ercusyn.eu/find-your-center/

Call for Scientific Ideas

All ERCUSYN partners are encouraged to send their scientific ideas on possible data analysis. Proposals will be evaluated by the scientific steering committee. The new deadline for receiving proposals is June 2020 (contact asantos@ercusyn.eu for proposals and more information).

Invitation to join the project:
The ERCUSYN project welcomes European centers of excellence who work with CS to join and contribute to the project, if they are prepared to include patients and update their outcome periodically. If interested please contact asantos@ercusyn.eu

The ERCUSYN project has received funding from the European Commission (PHD 800200) and is supported by the ESE and by unrestricted support from Novartis, Ipsen and HRA.